Litigation Details for GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
✉ Email this page to a colleague
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
Docket | ⤷ Sign Up | Date Filed | 2014-07-03 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:145 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | Plaintiff | Referred To | Christopher J. Burke |
Patents | RE40 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc.
Details for GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-03-28 | 489 | claims 1, 2, and 3 of U.S. Patent No . RE40,000 ("the '000 patent") by Defendant Teva Pharmaceuticals…377) The patent issued in June 1998 as U.S. Patent No. 5,760,069 (the "' 069 patent"), entitled…; 000 patent, the ' 069 patent was de-listed from the Orange Book, and the ' 000 patent was listed…further patent prosecution efforts, including to correct certain errors in the '069 patent. Consequently…January 8, 2008 , the ' 069 patent reissued as the ' 000 patent. (See Lukas Tr. at 373-74, 405 | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |